Paper Review Records
All Paper Review Records
19 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
88
days
Open‐Label, Balanced, Randomized, Single‐Dose, Three‐Treatment, Three‐Sequence, Three‐Period, Three‐Way Crossover Oral Bioequivalence Study of Desmopressin Acetate Oral Solution
AuthorsAdam Christensen; Axay Parth; Mansi Kotak; Danka Radosavjevic; Catherine Gorman Moore; Byung‐Woun Seo
Affiliations1. Eton Pharmaceuticals Deer Park IL USA; 2. Veeda Clinical Research, Mehsana Panchot India; 3. Veeda Clinical Research Ahmedabad Gujarat India
87
days
Safety, Tolerability, Pharmacokinetics, Food Effect of Ribitol, and Its Effect on QTcF in Healthy Adults: First‐in‐Human, Randomized, Double‐Blind (Sponsor Unblinded), Placebo‐Controlled Studies
AuthorsDaniel D. Gretler; Athiwat Hutchaleelaha; Uma Sinha; Kristen Rickert; Doug Sproule
Affiliations1. Bridgebio Pharma, Inc. Palo Alto CA USA
55
days
Phase 1 Study of Paltusotine, a Novel Oral Once‑Daily, Nonpeptide Selective Somatostatin Receptor 2 Agonist, in Healthy Japanese Adults
AuthorsFumio Otsuka; Keiko Hanabara; Seigo Akari; Katsunori Kitamoto; Yosuke Inagaki; Dylan Glatt; Harumi Murakami; Naoki Uchida
Affiliations1. Department of General Medicine Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan; 2. Medical Affairs Group Medical Affairs Department Sanwa Kagaku Kenkyusho Co., Ltd. Nagoya Japan; 3. Project Management Group Project Management Department Sanwa Kagaku Kenkyusho Co., Ltd. Nagoya Japan; 4. Clinical Development Department Sanwa Kagaku Kenkyusho Co., Ltd. Nagoya Japan; 5. Crinetics Pharmaceuticals, Inc. San Diego USA; 6. Souseikai Sumida Hospital Tokyo Japan; 7. Division of Clinical Pharmacology Department of Pharmacology Showa Medical University School of Medicine Tokyo Japan
43
days
Comparative bioavailability of a novel fixed‐dose combination of ticagrelor and acetylsalicylic acid
AuthorsSusana Tera‐Ponce; Perla E. Castañeda‐Tera; Elva J. García‐Real; Francisco Ávila‐García; Kevin F. Rios‐Brito; Laura A. Lugo‐Sánchez; Daniel E. Sandoval‐Colin; Paola M. Medina‐Cárdenas; Jorge González‐Canudas
Affiliations1. Department of Pharmacology Faculty of Medicine National Autonomous University of Mexico (UNAM) Mexico City Mexico; 2. Unidad Clínica Farmacológica Bioemagno S. A. de C. V Mexico City Mexico; 3. Bioanalit Laboratorios S.A. de C.V Mexico City Mexico; 4. Research and Development Department Laboratorios Silanes S.A. de C.V. Mexico City Mexico; 5. Mexican Social Security Institute (IMSS) Centro Médico Nacional Siglo XXI Mexico City Mexico
73
days
Pharmacokinetics and Bioequivalence of Tamsulosin Hydrochloride Extended‐Release Capsules in Healthy Chinese Volunteers: A Randomized, Open‐Label, Crossover Study Under Fasting and Fed Conditions
AuthorsLijie Du; Xiaolu Wang; Yi Zhang; Jiamin Yang; Fangliang Gan; Yaxun Pang
Affiliations1. School of Pharmacy Hubei University of Science and Technology Xianning China; 2. Phase I Clinical Research Center Xianning Central Hospital The First Affiliated Hospital of Hubei University of Science and Technology Xianning China; 3. Department of Neurosurgery Xianning Central Hospital The First Affiliated Hospital of Hubei University of Science and Technology Xianning China
98
days
Pharmacokinetics and Bioequivalence Study of Levodopa and Benserazide Tablets in Healthy Chinese Subjects Under Fasting and High‐Fat Meal Conditions
AuthorsYufei Liang; Yanchao Wang; Rui Shi; Yingzi Pei; Xiao Zhao; Qian Wang; Yanping Ren; Zekang Xie; Kexin Zhao
Affiliations1. Phase I Clinical Trials Center Hebei PetroChina Central Hospital Langfang China; 2. Department of Clinical Research Beijing Foyou Pharmaceutical Co., Ltd. Beijing China
119
days
Bioequivalence of Two Firsekibart Subcutaneous Formulations: A Randomized, Double‐Blind, Single‐Dose, Parallel‐Group Study in Healthy Chinese Participants
AuthorsYehua Xie; Xiao Li; Yushi Chen; Guangli Ma; Fei Gu; Yuling Lian; Xu Zhang; Xiaolan Yong
Affiliations1. Changchun GeneScience Pharmaceutical Co., Ltd. Shanghai China; 2. Phase I Clinical Trial Center Chengdu Xinhua Hospital Chengdu China
152
days
Comparison of ABBV‐552 Safety and Pharmacokinetics in Healthy Asian and Western Adults
AuthorsNick Miles; Brian McNamee; Cindy Zadikoff; Joey Boiser; Mohamad Shebley; Ramesh Boinpally
Affiliations1. Clinical Pharmacology AbbVie Inc. North Chicago IL USA; 2. Clinical Development Neuroscience AbbVie Inc. North Chicago IL USA; 3. Pharmacovigilance and Patient Safety AbbVie Inc. North Chicago IL USA
56
days
A Phase 1 Study to Assess the Relative Bioavailability of Brigatinib Administered as an Oral Solution Versus an Immediate‐Release Tablet in Healthy Adults
AuthorsMichael J. Hanley; Ronald Gounden; Bradley Hupf; Saurabh Sarkar; Robert J. Fram; Neeraj Gupta
Affiliations1. Takeda Development Center Americas, Inc. Cambridge MA USA
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days